Armistice Capital, LLC 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 5:22 pm Sale |
2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Armistice Capital, LLC | 7,358,000 9.620% |
-290,000 (-3.79%) |
Filing |
| 2024-11-14 5:13 pm Purchase |
2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX |
Armistice Capital, LLC | 7,648,000 10.000% |
264,000 (+3.58%) |
Filing |
| 2024-02-14 2:35 pm Purchase |
2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Armistice Capital, LLC | 7,384,000 9.830% |
972,000 (+15.16%) |
Filing |
| 2023-02-14 1:39 pm Purchase |
2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Armistice Capital, LLC | 6,412,000 9.990% |
2,334,000 (+57.23%) |
Filing |
| 2022-02-14 5:22 pm Purchase |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Armistice Capital, LLC | 4,078,000 6.700% |
4,078,000 (New Position) |
Filing |